Alexander L. Fogel, BS, Sharleen Hill, MD, Joyce M.C. Teng, MD, PhD

Slides:

Advertisements

Similar presentations

by Rogelio Zamilpa, and Merry L. Lindsey

Advertisements

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

A girl with a solitary red bulla

Facial adenocarcinoma treated with intra-arterial chemotherapy

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients Lucy Y. Liu, BA, Brittany.

Sweet's panniculitis associated with metastatic breast cancer

Hypertrichosis around a leg ulcer being treated with prostaglandin E1 ointment Tetsuya Honda, MD, PhD, Satoshi Koreeda, MD, PhD, Yoshiki Miyachi, MD,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Efficacy of topical application of eosin for ulcerated hemangiomas

The Akt-mTOR tango and its relevance to cancer

Trigeminal trophic syndrome secondary to recurrent meningioma

Kinase inhibitors: Vice becomes virtue

Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3- Kinase/AKT/Mammalian Target of Rapamycin Pathway Gozde Akgumus, Fengqi.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Clindamycin-induced Sweet syndrome

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.

JAK inhibitors in dermatology: The promise of a new drug class

Laser-assisted drug delivery: Enhanced response to ingenol mebutate after ablative fractional laser treatment Stephan Alexander Braun, MD, Peter Hevezi,

Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L

Katherine E. Brick, BS, Robert H. Cook-Norris, MD, David A

Figure 1 mTOR complex biology

In-vitro regulation of primordial follicle activation: challenges for fertility preservation strategies Michael J. Bertoldo, Kirsty A. Walters, William.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Applying for dermatology residency is difficult and expensive

Kishore L. Jayakumar, BS, Sara S. Samimi, MD

The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Duration of oral antibiotic therapy for the treatment of adult acne: A retrospective analysis investigating adherence to guideline recommendations and.

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Fever, eosinophilia, and a rash

Infectious rash after riding elephants

Inhibition of mammalian target of rapamycin: Two goals with one shot?

Gwanghyun Jo, MD, Je-Ho Mun, MD, PhD

Lip edema Journal of the American Academy of Dermatology

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

FGFR Signaling as a Target for Lung Cancer Therapy

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells

Figure 1 The mTOR signalling pathway

Charles E. Reed, MD, Hirohito Kita, MD

mTOR and Akt Signaling in Cancer: SGK Cycles In

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Hugh Gloster, MD, Chesahna Kindred, MBA

Seasonal patterns in alopecia areata, totalis, and universalis

Medicaid acceptance among pediatric dermatologists

Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn Kidney International

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing Richard A.F. Clark,

A new oral anticoagulant in the setting of dermatologic surgery

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

Update on the Medical Treatment of Metastatic Renal Cell Carcinoma

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

A grayscale photograph with high dynamic range taken under a Wood's lamp for better recognition of vitiligo lesions Jung Min Bae, MD, PhD, Tae Young.

Sirolimus for treatment of verrucous venous malformation: A retrospective cohort study Gaolei Zhang, MD, PhD, Hongguang Chen, MD, PhD, Zhen Zhen, MD,

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Nutrient Sensing, Metabolism, and Cell Growth Control

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Anastasia O. Kurta, DO, Daisy Dai, PhD, Eric S

Presentation transcript:

Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology Alexander L. Fogel, BS, Sharleen Hill, MD, Joyce M.C. Teng, MD, PhD Journal of the American Academy of Dermatology Volume 72, Issue 5, Pages 879-889 (May 2015) DOI: 10.1016/j.jaad.2015.01.014 Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 The mammalian target of rapamycin (mTOR) pathway and therapeutic targets. Akt, Protein kinase B; AMPK, 5' AMP-activated protein kinase; eIF4B, eukaryotic translation initiation factor 4b; FLCN, folliculin; GNAQ, guanine nucleotide-binding protein G(q); mTORC, mTOR complex; NF1, neurofibromin-1; PDK1, 3-phosphoinositide -dependent protein kinase-1; PI3K, phosphoinositide 3-kinase; PKCa, protein kinase C-alpha; PTHS, PTEN hamartoma tumor syndromes; REDD1, regulated in development and DNA damage responses-1; RHEB, Ras homolog enriched in brain; Rho, Rhodopsin; S6K, S6 kinase; TSC, tuberous sclerosis comple. Journal of the American Academy of Dermatology 2015 72, 879-889DOI: (10.1016/j.jaad.2015.01.014) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Tuberous sclerosis. Facial angiofibromas. Journal of the American Academy of Dermatology 2015 72, 879-889DOI: (10.1016/j.jaad.2015.01.014) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Facial angiofibroma in a 16-year-old girl treated with topical rapamycin. A, Before treatment. B, Substantial improvement noted after 12 weeks of treatment using topical rapamycin. Journal of the American Academy of Dermatology 2015 72, 879-889DOI: (10.1016/j.jaad.2015.01.014) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Pachyonychia congenita. Plantar callouses. Journal of the American Academy of Dermatology 2015 72, 879-889DOI: (10.1016/j.jaad.2015.01.014) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 5 Arterial venous malformation. Journal of the American Academy of Dermatology 2015 72, 879-889DOI: (10.1016/j.jaad.2015.01.014) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions